Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes

RW. Browne, B. Weinstock-Guttman, D. Horakova, R. Zivadinov, ML. Bodziak, M. Tamaño-Blanco, D. Badgett, M. Tyblova, M. Vaneckova, Z. Seidl, J. Krasensky, N. Bergsland, DP. Ramasamy, J. Hagemeier, E. Havrdova, M. Ramanathan,

. 2014 ; 85 (8) : 859-864.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie, Research Support, U.S. Gov't, Non-P.H.S.

Perzistentní odkaz   https://www.medvik.cz/link/bmc14074308

Grantová podpora
NT13237 MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Článek
Zdroj

E-zdroje Online Plný text

NLK ProQuest Central od 1944-07-01 do Před 6 měsíci
Nursing & Allied Health Database (ProQuest) od 1944-07-01 do Před 6 měsíci
Health & Medicine (ProQuest) od 1944-07-01 do Před 6 měsíci
Psychology Database (ProQuest) od 1944-07-01 do Před 6 měsíci

Odkazy

PubMed 24470599
DOI 10.1136/jnnp-2013-307106
Knihovny.cz E-zdroje

OBJECTIVES: There is increasing evidence that serum lipoprotein cholesterol biomarkers are associated with disease progression in clinically isolated syndromes (CIS). Apolipoproteins (Apo) are recognition ligands that mediate the physiological interactions of cholesterol-containing lipoproteins. The objective of this study was to investigate whether serum Apo levels are associated with CIS disease progression. METHODS: ApoB, ApoAI, ApoAII, ApoE and lipoprotein (a) (Lpa) levels were measured in serum samples obtained prior to the start of treatment from 181 CIS patients (123 women, 58 men, 68% women; mean age: 28.1±SD 8.1 years). All patients were treated with intramuscular interferon-β as part of the prospective study. Clinical and MRI assessments were obtained at baseline, 6, 12 and 24 months after start of interferon-β treatment. RESULTS: Greater ApoB levels were associated with increased number of new T2 lesions (p<0.001) and increased number of new or enlarging T2 lesions (p<0.001) over 2 years. Each 10 mg/dL of greater baseline ApoB is associated with a 16% increase in the number of new T2 lesions over 2 years. ApoAI, ApoAII, ApoE and Lpa were not associated with T2 lesions. Greater ApoE levels were associated with greater deep grey matter atrophy (partial correlation rp=-0.28, p<0.001). Each 1 mg/dL increment in ApoE levels was associated with a 1% increase in deep grey matter atrophy over 2 years. CONCLUSIONS: Serum ApoB levels are associated with new lesion accumulation whereas ApoE levels are associated with deep grey matter atrophy in high risk CIS patients treated with interferon β-1a.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14074308
003      
CZ-PrNML
005      
20181023155048.0
007      
ta
008      
141006s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/jnnp-2013-307106 $2 doi
035    __
$a (PubMed)24470599
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Browne, Richard W $u Department of Biotechnical and Clinical Laboratory Sciences, State University of New York, Buffalo, New York, USA.
245    10
$a Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes / $c RW. Browne, B. Weinstock-Guttman, D. Horakova, R. Zivadinov, ML. Bodziak, M. Tamaño-Blanco, D. Badgett, M. Tyblova, M. Vaneckova, Z. Seidl, J. Krasensky, N. Bergsland, DP. Ramasamy, J. Hagemeier, E. Havrdova, M. Ramanathan,
520    9_
$a OBJECTIVES: There is increasing evidence that serum lipoprotein cholesterol biomarkers are associated with disease progression in clinically isolated syndromes (CIS). Apolipoproteins (Apo) are recognition ligands that mediate the physiological interactions of cholesterol-containing lipoproteins. The objective of this study was to investigate whether serum Apo levels are associated with CIS disease progression. METHODS: ApoB, ApoAI, ApoAII, ApoE and lipoprotein (a) (Lpa) levels were measured in serum samples obtained prior to the start of treatment from 181 CIS patients (123 women, 58 men, 68% women; mean age: 28.1±SD 8.1 years). All patients were treated with intramuscular interferon-β as part of the prospective study. Clinical and MRI assessments were obtained at baseline, 6, 12 and 24 months after start of interferon-β treatment. RESULTS: Greater ApoB levels were associated with increased number of new T2 lesions (p<0.001) and increased number of new or enlarging T2 lesions (p<0.001) over 2 years. Each 10 mg/dL of greater baseline ApoB is associated with a 16% increase in the number of new T2 lesions over 2 years. ApoAI, ApoAII, ApoE and Lpa were not associated with T2 lesions. Greater ApoE levels were associated with greater deep grey matter atrophy (partial correlation rp=-0.28, p<0.001). Each 1 mg/dL increment in ApoE levels was associated with a 1% increase in deep grey matter atrophy over 2 years. CONCLUSIONS: Serum ApoB levels are associated with new lesion accumulation whereas ApoE levels are associated with deep grey matter atrophy in high risk CIS patients treated with interferon β-1a.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a antiflogistika $x terapeutické užití $7 D000893
650    _2
$a apolipoproteiny $x metabolismus $7 D001053
650    _2
$a apolipoproteiny E $x krev $7 D001057
650    _2
$a atrofie $7 D001284
650    _2
$a mozek $x patologie $7 D001921
650    _2
$a interpretace statistických dat $7 D003627
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a počítačové zpracování obrazu $7 D007091
650    _2
$a lipidy $x krev $7 D008055
650    _2
$a longitudinální studie $7 D008137
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a methylprednisolon $x terapeutické užití $7 D008775
650    _2
$a lidé středního věku $7 D008875
650    _2
$a roztroušená skleróza $x metabolismus $x patologie $7 D009103
650    _2
$a prospektivní studie $7 D011446
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
655    _2
$a Research Support, U.S. Gov't, Non-P.H.S. $7 D013486
700    1_
$a Weinstock-Guttman, Bianca $u Department of Neurology, State University of New York, Buffalo, New York, USA.
700    1_
$a Horáková, Dana $u Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. $7 xx0076527
700    1_
$a Zivadinov, Robert $u Department of Neurology, State University of New York, Buffalo, New York, USA Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York, Buffalo, New York, USA.
700    1_
$a Bodziak, Mary Lou $u Department of Biotechnical and Clinical Laboratory Sciences, State University of New York, Buffalo, New York, USA.
700    1_
$a Tamaño-Blanco, Miriam $u Department of Pharmaceutical Sciences, State University of New York, Buffalo, New York, USA.
700    1_
$a Badgett, Darlene $u Department of Pharmaceutical Sciences, State University of New York, Buffalo, New York, USA.
700    1_
$a Týblová, Michaela $u Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. $7 xx0121850
700    1_
$a Vaněčková, Manuela, $u Department of Radiology, 1st Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. $d 1973- $7 mzk2007377403
700    1_
$a Seidl, Zdeněk, $u Department of Radiology, 1st Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. $d 1950- $7 mzk2004258727
700    1_
$a Krásenský, Jan $u Department of Radiology, 1st Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. $7 xx0096156
700    1_
$a Bergsland, Niels $u Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York, Buffalo, New York, USA.
700    1_
$a Ramasamy, Deepa P $u Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York, Buffalo, New York, USA.
700    1_
$a Hagemeier, Jesper $u Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York, Buffalo, New York, USA.
700    1_
$a Kubala Havrdová, Eva, $u Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. $d 1955- $7 nlk19990073204
700    1_
$a Ramanathan, Murali $u Department of Neurology, State University of New York, Buffalo, New York, USA Department of Pharmaceutical Sciences, State University of New York, Buffalo, New York, USA.
773    0_
$w MED00010064 $t Journal of neurology, neurosurgery and psychiatry $x 1468-330X $g Roč. 85, č. 8 (2014), s. 859-864
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24470599 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20141006 $b ABA008
991    __
$a 20181023155555 $b ABA008
999    __
$a ok $b bmc $g 1042191 $s 873220
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 85 $c 8 $d 859-864 $i 1468-330X $m Journal of neurology, neurosurgery and psychiatry $n J Neurol Neurosurg Psychiatry $x MED00010064
GRA    __
$a NT13237 $p MZ0
LZP    __
$a Pubmed-20141006

Najít záznam

Citační ukazatele

Možnosti archivace